Sanofi Consumer Healthcare Reports Q4FY25 Results Under Regulation 30
Sanofi Consumer Healthcare India Limited reported exceptional Q4FY25 and FY25 results under Regulation 30, with quarterly revenue growing 47% to ₹2,510 million and net profit surging 50% to ₹665 million. Annual performance showed revenue of ₹8,784 million (up 21%) and net profit of ₹2,401 million (up 33%), supported by successful product relaunches and strong domestic and export sales growth.
*this image is generated using AI for illustrative purposes only.
Sanofi Consumer Healthcare India Limited has announced outstanding financial results for Q4FY25 and FY25, demonstrating exceptional growth across all key performance metrics. The consumer healthcare company reported strong results following the Board meeting held on February 25, 2026, with audited standalone financial statements showing remarkable improvement in profitability and revenue generation under Regulation 30 of SEBI Listing Obligations.
Q4FY25 Performance Highlights
The fourth quarter performance continued the strong momentum, with quarterly results showing exceptional growth patterns across key metrics, maintaining the positive trajectory throughout FY25.
| Q4 Performance: | Q4 FY25 | Q4 FY24 | Year-on-Year Change |
|---|---|---|---|
| Quarterly Net Profit: | ₹665 million | ₹443 million | +50% |
| Quarterly Revenue: | ₹2,510 million | ₹1,707 million | +47% |
| Quarterly EPS: | ₹28.87 | ₹19.25 | +50% |
| Domestic Sales Growth: | - | - | +23% |
| Export Sales Growth: | - | - | +932% |
Annual Financial Performance Overview
The company's full-year results reveal substantial improvement across all financial parameters, reflecting strong market performance and effective business execution strategies.
| Financial Metric: | FY25 | FY24 | Growth (%) |
|---|---|---|---|
| Annual Net Profit: | ₹2,401 million | ₹1,810 million | +33% |
| Annual Revenue: | ₹8,784 million | ₹7,245 million | +21% |
| Annual EBITDA: | ₹3,137 million | ₹2,752 million | +14% |
| Earnings Per Share: | ₹104.27 | ₹78.59 | +33% |
| Domestic Sales Growth: | - | - | +7% |
| Export Sales Growth: | - | - | +158% |
Management Commentary and Strategic Outlook
Commenting on the Q4FY25 results, Himanshu Bakshi, Managing Director, emphasized the strength of the core portfolio and disciplined execution of growth agenda. The domestic business delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from export markets. The company remains focused on reinforcing brand fundamentals and driving operational excellence to unlock sustainable growth.
Amit Jain, Chairman, highlighted that the full-year performance reflects strategic strength and disciplined execution by teams. The company drove sustained growth, deepened portfolio penetration, and accelerated digital transformation, delivering meaningful outcomes for stakeholders.
Board Decisions and Dividend Declaration
The Board of Directors has recommended a final dividend of ₹75 per equity share of face value ₹10 each for FY25, subject to shareholder approval at the upcoming Annual General Meeting. The Board also approved the re-appointment of M/s. Kishore Bhatia & Associates, Cost Accountants as Cost Auditor for FY26, subject to shareholder ratification.
Business Recovery and Product Portfolio
The company successfully navigated product recall challenges from the previous year, with successful relaunches of key products including Depura Adult, Combiflam Suspension, Allegra Suspension, and Depura Kids across different quarters of FY25. This recovery contributed significantly to the improved financial performance and market position, supporting the strong domestic sales growth of 23% in Q4FY25.
The annual results demonstrate Sanofi Consumer Healthcare's resilient business model and strong execution capabilities, positioning the company well for continued growth in the consumer healthcare segment with robust financial fundamentals and operational excellence.
Historical Stock Returns for Sanofi Consumer Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.24% | -4.08% | -1.71% | -22.36% | -13.14% | -18.24% |
15
